Purpose: To investigate the anti-hyperprolactinemic effect of Ficus pumila Linn. extract (FPLE) 
INTRODUCTION
Hyperprolactinemia, defined as a prolactin (PRL) level greater than 25 ng/ml, is one of the most common endocrine disorders of the hypothalamus-pituitary axis in young women. It is associated with galactorrhea and ovulatory dysfunction, resulting in menstrual irregularities and bareness [1] . Hyperprolactinemia can occur at any age, and its prevalence varies from 0.4 % in the normal adult population to 9 -17 % in women with menstrual problems such as amenorrhea or polycysticovarian syndrome [2, 3] . Causes of hyperprolactinemia include hypothalamus-pituitary lesions, pituitary tumors, severe liver or kidney disease, neuritis or irritations of the spinal cord, depression, or other physiological factors such as pregnancy and lactation [4, 5] . The pharmacological agents currently used to treat hyperprolactinemia cause many side effects, such as menstrual disorder, and are associated with high relapse rates. Although bromocriptine and cabergoline are effective in treating hyperprolactinemia, they are very expensive [7] , and 12 % patients cannot tolerate bromocriptine [6] .
Since the Song Dynasty, Ficus pumila Linn. has been used to effectively treat Chinese women with galactorrhea without toxic side effects [8] [9] . Therefore, we evaluated the anti-hyperprolactinemic effect of Ficus pumila Linn. extract (FPLE) on serum sex hormone levels and pituitary prolactin (PRL)-positive cell number and mRNA expression in rats. [10] .
EXPERIMENTAL Materials

Preparation of hyperprolactinemic rats and FPLE treatment
Hyperprolactinemic rats were generated as previously described with slight modifications [11] . Metoclopramide dihydrochloride (50 mg/kg) was subcutaneously injected into the back of rats. Injections were performed twice a day for 5 consecutive days.
Rats were divided into six groups (n = 10 per group): normal control, model (i.e., hyperprolactinemic), model plus bromocriptine, model plus high dose of FPLE (800 mg/kg), model plus moderate dose of FPLE (400 mg/kg), and model plus low dose of FPLE (200 mg/kg).
Each dose of FPLE was dissolved in 2 ml water and administered through the mouth to the stomach by a syringe. The dosage for rats was calculated from the human clinical daily dosage of FPLE based on differences in body surface area. Control and model rats received 2 ml of water only. All rats received intragastric administration for 30 days.
Measurements of serum sex hormones
After intragastric administration for 30 days, serum estradiol (E2), progesterone (P), PRL, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured. All measurements were performed using ELISA kits from Nanjing Jiancheng Inc. (China).
Quantification of pituitary PRL-positive cells
Rat pituitary tissue was embedded in paraffin wax. After dewaxing, tissue was incubated with 3 % H 2 O 2 for 5 min at room temperature. Anti-rat PRL antibody (primary antibody, 1:300) was applied for 60 min at room temperature, and tissue was washed with phosphate-buffered saline (PBS) three times. Next, tissue was incubated in EnVision reagent including secondary and tertiary antibodies for 60 min at room temperature and washed with PBS three times. Tissue was stained with DAB solution, washed with distilled water, and restained. PRLpositive cells were counted using Microsoft software at 200× magnification.
Measurement of pituitary PRL mRNA expression
Pituitary tissue was placed into a glass grinder with 1 ml Trizol solution. The homogenate was placed into a 1.5-ml Eppendorf tube and kept at room temperature for 5 min before adding 0.25 ml chloroform, shaking for 15 s, and resting for 3 min at room temperature. The solution was centrifuged (12000× g) for 15 min at 4 o C. The upper aqueous portion was added to an equal volume of isopropyl alcohol in a 1.5-ml Eppendorf tube and kept for 10 min at room temperature before centrifugation (12000× g) for 10 min at 4 o C.
The supernatant was discarded, 0.9 ml 75 % ethanol was added, and the solution was centrifuged (10000× g) for 5 min at 4 o C; this step was repeated once. The supernatant was discarded, and the precipitant was dried at room temperature. Next, 30 -50 μl RNase-free water was added to dissolve the RNA sample. The RNA sample and primer underwent PCR at 95 
Statistical analysis
Data are shown as mean ± standard error of the mean unless otherwise indicated. Differences between groups were analyzed using one-way analysis of variance (ANOVA) followed by Student's t-tests. A p-value < 0.05 was considered statistically significant.
RESULTS
Effect of FPLE on serum sex hormones levels
Rats in the model group showed significantly higher serum PRL levels (p < 0.01) and lower E2 (p < 0.01), P (p < 0.01), FSH (p < 0.01), and LH (p < 0.05) levels than rats in the control group (Table 1) . The increased PRL levels in model rats were significantly attenuated by treatment with bromocriptine (p < 0.01), a moderate dose of FPLE (p < 0.01), or a high dose of FPLE (p < 0.01). Bromocriptine, a moderate dose of FPLE, and a high dose of FPLE also significantly increased E2 (p < 0.01), P (p < 0.01), FSH (p < 0.05), and LH (p < 0.05) levels.
Effect of FPLE on pituitary PRL-positive cell number
The number of pituitary PRL-positive cells was significantly higher in model rats than in control rats (p < 0.01; Figure 1 ). This increased number of PRL-positive cells in model rats was significantly attenuated by treatment with bromocriptine (p < 0.01), a moderate dose of FPLE (p < 0.05), and a high dose of FPLE (p < 0.01). 
Effect of FPLE on pituitary PRL mRNA expression
Model rats showed significantly higher PRL mRNA expression than control rats (p < 0.01; Figures 2-3 ). This increased PRL mRNA expression in model rats was significantly attenuated by treatment with bromocriptine (p < 0.01), a moderate dose of FPLE (p < 0.05), and a high dose of FPLE (p < 0.01).
DISCUSSION
The hypothalamus-pituitary-gonadal axis plays an important role in maintaining normal physiological body function and homeostasis of the internal environment [12] . However, external factors can lead to abnormal sex hormone secretion and result in conditions such as hyperprolactinemia, hyperplasia of the mammary gland, hysteromyoma, and infertility. In mammals, PRL regulates mammogenesis, promotes milk production, and initiates and sustains lactation through autocrine and paracrine signaling [13, 14] . PRL has many functions in breast tissue, including uridine conversion, milk protein synthesis, mammary cell sodium transport, incorporation into DNA, and breast fatty acid synthetase activity [15] . We found that hyperprolactinemic rats showed higher serum PRL concentrations, as well as lower E2, P, FSH, and LH concentrations than control rats. However, FPLE attenuated the effects of hyperprolactinemia on serum sex hormone levels, suggesting that FPLE improves ovary function and reduces hyperplasia of the lobules and gland alveolus. Furthermore, FPLE decreased pituitary PRL-positive cell number and mRNA expression in hyperprolactinemic rats.
CONCLUSION
The results confirm that Ficus pumila Linn. has curative effects in hyperprolactinemia and suggest that FPLE treatment can regulate serum E2, P, PRL, FSH, and LH levels and decrease pituitary PRL-positive cell number and mRNA expression in women with hyperprolactinemia. Therefore, FPLE should be developed as an antihyperprolactinemia treatment in future work.
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